Aplastic anaemia

All blood cells descend from a small population of haematopoietic stem cells living in the bone marrow. In aplastic anaemia that population collapses. Under the microscope the marrow — normally crowded with developing cells — looks empty, replaced by fat; in the bloodstream, all three cell lines dwindle together, a pattern called pancytopenia. The name is misleading in two ways worth correcting immediately: it is not just an anaemia, because white cells and platelets fail alongside red cells; and it is not a leukaemia — nothing is multiplying out of control, the problem is production shutting down.

In most acquired cases the mechanism is autoimmune: the body’s own T-lymphocytes mistakenly attack the blood-forming stem cells. This single fact organises the whole treatment landscape, because it means the disease can be approached from two directions — restrain the attacking immune system with immunosuppressive drugs and let the surviving stem cells recover, or replace the stem cell population entirely with a donor’s through a transplant. Both approaches are established, both can restore normal blood production, and choosing between them is the central decision of the disease.

Aplastic anaemia is rare, with a peak in adolescents and young adults and a second peak in older age. It must be carefully distinguished from conditions that mimic it — hypoplastic myelodysplastic syndrome, hairy cell leukaemia, marrow infiltration — and from the inherited marrow-failure syndromes, such as Fanconi anaemia and the telomere disorders, which can present at similar ages but need entirely different treatment, different transplant conditioning, and family screening. A meaningful minority of patients also carry a small clone of cells with a condition called paroxysmal nocturnal haemoglobinuria (PNH), which links the two diseases and is tested for at diagnosis. Getting this differential right is why the diagnosis belongs in a specialist haematology unit from the start.

Because the disease is rare, experience concentrates: most countries treat severe aplastic anaemia in a handful of centres, and international referral is common — which for the purposes of this platform means the disease travels comparatively well. The evaluation is laboratory-based, the treatments are protocolised, and nothing about the condition demands the patient’s home city; what it does demand is speed once severity is established, and unbroken supportive care in the meantime. Families weighing options abroad should therefore run enquiries in parallel with, never instead of, local stabilisation.

The symptoms of aplastic anaemia are the symptoms of missing blood cells, arriving together and building over weeks to months — usually more gradually than acute leukaemia, which is one of the clinical clues separating them. The missing red cells bring fatigue that rest does not repair, breathlessness on exertion, pallor, headaches and a pounding awareness of the heartbeat. The missing platelets show first in the skin and mucous membranes: bruises out of proportion to any knock, showers of pinpoint red-purple dots on the lower legs, bleeding gums at toothbrushing, nosebleeds that take too long to stop, heavy periods. The missing neutrophils reveal themselves as infections — mouth ulcers, skin infections, sore throats, fevers — that recur or refuse to clear.

What is absent matters as much as what is present. Aplastic anaemia does not typically enlarge lymph nodes, the spleen or the liver; there is usually no bone pain; weight is usually preserved early on. A doctor finding pancytopenia with none of those features begins to think of marrow failure rather than marrow invasion. Some patients are found before symptoms at all, when a blood count taken for another reason returns low across all three lines. The tempo distinguishes it usefully from its acute mimics: leukaemia tends to declare in days to weeks, aplastic anaemia in weeks to months — long enough that patients often reorganise life around the fatigue (afternoon rests, dropped commitments) before medicine gets involved, a pattern worth describing to the assessing doctor because the timeline itself is diagnostic information.

Because the fall is often gradual, people adapt without noticing — blaming work, age or stress for the fatigue until a bleed or an infection forces attention. The practical message mirrors the other blood-failure diseases on this platform: unexplained bruising plus unusual infections plus mounting exhaustion is a combination that has earned a full blood count this week, not this quarter.

In most acquired aplastic anaemia, the direct cause is an autoimmune attack: cytotoxic T-cells target the marrow’s stem cells and shut production down. What triggers that attack usually cannot be identified in the individual — the majority of cases are labelled idiopathic — but several recognised precipitants exist. Certain medicines are rare but established triggers, historically including chloramphenicol and some anti-thyroid, anti-epileptic and anti-inflammatory drugs; the reactions are unpredictable and unrelated to dose. The practical corollary cuts both ways: no blame attaches to having taken a implicated medicine for good reason, and no protection comes from avoiding medicines wholesale — the absolute risks are tiny, and untreated epilepsy or hyperthyroidism harms far more surely than their rare marrow reactions. Benzene and some industrial solvents and pesticides are established environmental causes, and are the reason occupational exposure limits exist. Viral hepatitis — typically a recent episode, with the usual hepatitis viruses often NOT identifiable — precedes a recognised subset called hepatitis-associated aplastic anaemia, which particularly affects young men. Radiation damages marrow directly and dose-dependently. Pregnancy is a rare association that sometimes remits after delivery.

Separated from all of these are the inherited marrow-failure syndromes, which are not autoimmune at all: Fanconi anaemia, dyskeratosis congenita and other telomere biology disorders, Shwachman–Diamond syndrome and others. They can first declare themselves in adolescence or adulthood, sometimes without the classic physical signs, which is why specialist units screen younger patients — and any patient with suggestive features or family history — with chromosome fragility and telomere-length tests. The distinction is not academic: inherited disease does not respond to immunosuppression, requires adjusted transplant conditioning, and rules certain relatives out as donors because they may silently carry the same disorder.

Aplastic anaemia is rare enough that its risk factors describe faint statistical shadows rather than destinies. Age shows two peaks — roughly the teens-to-twenties and older adulthood. Exposure to benzene and related solvents, certain pesticides, and ionising radiation carry established occupational risk, concentrated in industries where controls fail. A recent episode of hepatitis, particularly in a young man, precedes the hepatitis-associated form. A long list of medicines carries rare idiosyncratic risk — worth an honest medication review at diagnosis, though rarely a cause for blame, since the reactions are unpredictable. A family history of marrow failure, early greying, nail and skin changes, pulmonary fibrosis or unexplained cirrhosis raises the question of an inherited telomere disorder. PNH and aplastic anaemia travel together often enough that each diagnosis prompts testing for the other.

As elsewhere on this platform’s blood pages, the popular-suspicion list deserves its clearing: vaccines, mobile phones, everyday stress and ordinary diagnostic X-rays have no credible link to aplastic anaemia. The documented causes are the specific ones above, and most patients have none of them — a truth that redirects energy from retrospection to the treatment decisions that actually change outcomes.

Severity in aplastic anaemia is graded by internationally used criteria (the Camitta criteria) that combine marrow emptiness with how far the blood counts have fallen. The grade is not bureaucracy — it directly drives how urgently and how aggressively the disease is treated.

The route in is almost always a full blood count showing pancytopenia, with a reticulocyte count confirming that the marrow is not responding as a healthy marrow would. The blood film matters for what it lacks: no blasts, no abnormal cells — emptiness, not invasion. From there the diagnosis is made in the marrow. A bone marrow aspirate and trephine biopsy, taken from the pelvis under local anaesthetic, shows a strikingly hypocellular marrow with the remaining space occupied by fat; the trephine (the solid core) is essential, because cellularity cannot be judged from liquid aspirate alone.

The rest of the work-up exists to exclude the mimics and identify the variants, because each changes management. Cytogenetics on the marrow looks for the chromosomal abnormalities that would point instead to hypoplastic myelodysplastic syndrome. Flow cytometry on blood tests for a PNH clone. Chromosome fragility testing (for Fanconi anaemia) and telomere length testing screen for inherited syndromes — routine in children and younger adults, and used selectively in older patients with suggestive features. Vitamin B12 and folate levels, viral serology (hepatitis viruses, EBV, CMV, HIV, parvovirus B19), autoimmune screens and a careful drug and occupational history complete the picture.

Two practical tests run alongside diagnosis rather than after it. HLA typing of the patient — and siblings, where transplant could be an option — starts immediately, because sibling-donor transplant is first-line treatment for younger patients with severe disease, and the search must not wait for a treatment decision it is itself part of. And baseline organ assessments (heart, lungs, liver, kidneys) quietly gather the fitness evidence that both intensive immunosuppression and transplant will require.

A note on how results read: marrow cellularity is judged against age (a healthy young marrow is mostly cells; an elderly one, mostly fat), so the same biopsy picture means different things at 20 and 70 — one reason the trephine goes to specialist pathologists. And a single normal count line does not exclude the disease: platelets often fall first and furthest, and the diagnosis is made on the pattern across all three lines plus the marrow, not on any threshold alone.

These are the values quoted at every clinic visit, what each measures, and why they matter in marrow failure specifically.

The dangerous complications of untreated severe aplastic anaemia are the direct consequences of the missing cells. Infection leads: with neutrophils nearly absent, bacterial and fungal infections can escalate in hours, which is why fever in this disease is treated as an emergency everywhere and why very severe grades are nursed under protective policies. Bleeding is second: platelet counts at the levels severe disease produces make spontaneous bleeding possible, and intracranial bleeding — rare — is the feared version. Severe anaemia strains the heart, particularly in older patients.

Treatment and time add their own layer. Repeated red cell transfusions load the body with iron it cannot excrete; over years, unchecked iron overload injures the liver and heart, which is why ferritin is tracked and chelation therapy is used when needed. Immunosuppressive therapy brings infection risk of its own and, with ciclosporin, kidney and blood pressure effects that need monitoring. Two long-term risks belong to the disease’s biology rather than its treatment: a minority of patients, over years, evolve a clonal marrow disorder — myelodysplastic syndrome or AML — and some develop or expand a PNH clone; both are the reason follow-up in aplastic anaemia continues for life, even after an apparently complete recovery. Transplanted patients exchange these risks for the transplant’s own — graft rejection, graft-versus-host disease — discussed in the pathway section below.

Menstruation deserves a specific line, because in young women it can be both a presenting symptom and an ongoing management issue while platelets are low: heavy periods on a count of ten deserve proactive hormonal suppression, routinely offered in specialist units, not stoicism. Similarly practical: dental work, tattoos and piercings wait for recovered counts; and travel during the treatment year is planned with the unit, not around it, since a fever abroad needs a plan before departure.

Most aplastic anaemia cannot be prevented — the idiopathic majority strikes without an identifiable exposure. The preventable margin is occupational and environmental: proper handling of benzene and solvents, respect for radiation protection rules, and prudent use of the medicines with known (rare) marrow toxicity, taken only for real indications and stopped when counts fall unexplained. None of this is within a patient’s power after diagnosis — but a second category very much is: preventing complications while counts are low.

That means treating fever as the emergency it is, without waiting to see whether it settles; meticulous dental and skin hygiene, because mouths and skin are where infections start; avoiding aspirin and other drugs that impair the platelets a patient does still have, unless a doctor has said otherwise; using a soft toothbrush and avoiding contact sports while platelets are very low; and food-safety common sense during the deepest neutropenic phases, per the treating unit’s advice. Vaccination is coordinated with the haematology team — timing matters around immunosuppression and transplant, and live vaccines are avoided in specific windows. Family members can help most concretely by being HLA-typed promptly when asked, and — for the wider public — by joining donor registries and giving blood: an aplastic anaemia patient may receive dozens of donated units on the way to recovery.

For family members weighing donation itself: stem cell donation today usually means peripheral collection — injections for a few days, then a session on an apheresis machine — with marrow harvest under anaesthetic reserved for specific indications; both are established, well-tolerated procedures with decades of donor follow-up behind them. A sibling found to be a match faces a genuine choice, made with counselling and without pressure — a principle transplant units enforce protectively, since family love and family pressure can look alike from the outside. Donors are typically fit for ordinary life within days of peripheral collection, and registries following donors for decades report no long-term harm attributable to donation itself — facts worth having in the family conversation.

Severe aplastic anaemia has two definitive treatments, built on opposite logics. The first restrains the attacker: immunosuppressive therapy (IST), classically the combination of anti-thymocyte globulin (ATG) — an infusion course given in hospital — with ciclosporin tablets continued for many months. Horse-derived ATG has outperformed the rabbit form in comparative studies and is preferred where available. In recent years the thrombopoietin-receptor agonist eltrombopag, which stimulates surviving stem cells, has been added to IST after trials showed higher and faster response rates; the triple combination has become a widely used standard for patients not proceeding to transplant. Responses build over three to six months — patience is part of the protocol — and roughly speaking, most patients respond substantially, a minority completely; relapse and non-response are the recognised limitations, managed with a second course, eltrombopag-based regimens, or transplant. Response, when it comes, has a recognisable grammar worth teaching patients: transfusion independence usually arrives first, then reticulocytes climb, then neutrophils steady, with platelets — stubbornly — last, sometimes trailing by months; a partial response that keeps someone safe and untransfused is a genuine success even when counts never rewrite the textbook, and decisions about second-line treatment weigh exactly that distinction.

The second road replaces the marrow: allogeneic stem cell transplantation. For children and younger adults with severe disease and an HLA-matched sibling, transplant is generally recommended FIRST-line — it offers the highest chance of permanent cure, and outcomes from matched sibling transplant in young patients are among the best in all of transplant medicine. Conditioning for aplastic anaemia is designed differently from leukaemia protocols: the marrow is empty rather than cancerous, so the aim is immune suppression sufficient for engraftment, not tumour kill — and radiation is generally avoided. Matched unrelated donor transplant, once reserved for IST failures, has improved to the point where many centres now offer it earlier, particularly in the young; haploidentical (half-matched family) transplant extends the option further where no matched donor exists.

Around both roads runs supportive care that is lifesaving in itself: transfusions to bridge the counts (irradiated blood products, and leucodepleted, to protect future transplant options), rapid antibiotic protocols for fever, antifungal prophylaxis in prolonged neutropenia, and iron chelation when transfusion burden accumulates. Untreated severe disease has a grim natural history — which is precisely why “watch and wait” is reserved for genuinely non-severe cases, and why the treatment decision is made in weeks, not seasons.

The daily texture of treatment differs sharply by road. ATG is an inpatient week with infusion reactions managed at the bedside, followed by months of outpatient ciclosporin with blood-level checks; response declares itself slowly, and the units teach patience explicitly, because week six often looks no different from week one while week twenty looks transformed. Transplant compresses the story: weeks in hospital, then a taper measured in months. On either road, life between hospital contacts is governed by the counts — the fever rule, the soft toothbrush, the deferred contact sports — and by a support system that units help families build before discharge rather than after the first crisis.

Aplastic anaemia occupies a special place in transplant medicine: it is the non-cancer disease where a stem cell transplant is most often the FIRST choice rather than the last. For a child or younger adult with severe disease and an HLA-matched sibling, guidelines internationally recommend proceeding straight to transplant, because a successful graft replaces the failed marrow permanently, removes the relapse and clonal-evolution risks that follow immunosuppression, and — in this young, matched-sibling setting — carries some of the best outcomes in the field. With age the balance shifts: transplant toxicity and graft-versus-host risk rise, and IST becomes the usual first move, with transplant as the response to failure or relapse.

The transplant itself differs from the leukaemia version in ways patients notice. Conditioning is gentler in intent — its job is to prevent rejection, not to eradicate a cancer — typically built on cyclophosphamide and fludarabine with ATG or alemtuzumab, avoiding irradiation in most protocols. Because the recipient’s immune system is intact (unlike a chemotherapy-exhausted leukaemia patient’s), rejection is a real concern, and minimising pre-transplant transfusions — and always using irradiated, leucodepleted products — protects the graft’s chances. Donor hierarchy follows matching: matched sibling first, then matched unrelated donors through the international registries, then haploidentical family donors under modern post-transplant cyclophosphamide protocols, which have widened access markedly. One caveat is specific to this disease: when an inherited marrow-failure syndrome is possible, potential family donors are screened for it first — a silently affected sibling must not donate.

For families considering treatment abroad, the file a transplant centre needs is: the diagnostic marrow reports including cytogenetics, the severity grading and transfusion history, results of PNH, fragility and telomere testing, the patient’s HLA type and any family typing already done, and full records of any immunosuppressive treatment. Aplastic anaemia transplants are time-sensitive rather than emergencies — but months lost to disorganised paperwork are months of infection and bleeding risk, so assembling that file early is the single most useful preparatory step; the stem cell transplant guide describes the procedure itself.

The transformation of aplastic anaemia is one of haematology’s quiet success stories. A disease that once carried a dismal natural history is now, for most patients who reach definitive treatment, survivable — and for many, curable. Broad patterns hold across published series: young patients transplanted from matched siblings do best of all, with long-term survival in the high ranges and most survivors living unrestricted lives; matched unrelated donor results in experienced centres have climbed towards sibling results; immunosuppressive therapy produces meaningful responses in the majority, with eltrombopag improving both speed and completeness, at the cost of relapse in a minority and a long-term watch for clonal evolution.

What the outlook asks of patients is follow-up. After IST, counts and clinic visits continue for years: relapse is treatable when caught, and the small late risks of MDS, AML and PNH are exactly what scheduled marrow checks exist to catch early. After transplant, follow-up shifts to the transplant clinic’s rhythm — immunosuppression tapering, GvHD surveillance, revaccination — and then thins out as years accumulate. Precise percentages vary by age band, era and centre, and this page deliberately points to its sources rather than quoting numbers that would date; the honest summary is that both roads lead most patients back to school, work and ordinary life, and that the biggest modifiable factor remains the unglamorous one — reaching a specialist unit, with the diagnosis complete, without months of drift.

Recovered patients — by either road — mostly return to full lives: studies of long-term survivors show ordinary employment, families and activity. What persists is a follow-up habit: annual bloods for the IST-treated (relapse and clonal change are treatable when caught), transplant-clinic rhythms for the grafted, and for everyone a lower threshold for checking odd bruises or stubborn infections. Pregnancy after recovery is usually possible and is planned WITH the haematology team, since it can occasionally stress a recovered marrow. The disease that once defined a year of life becomes, for most, a line in the medical history.

The rarer trajectories deserve honest inclusion: a minority relapse after IST and are retreated or transplanted; a smaller minority evolve clonal disease years later, which scheduled marrows exist to catch at the treatable stage; and refractory disease — failing multiple lines — enters territory where experimental agents and second transplants are weighed case by case at referral centres. Even these harder paths have organised medicine waiting on them, which is the difference specialist follow-up makes.